Stallion IndiaQ4 FY25
Stallion India Q4 FY25 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹225P/E: 50.2Market Cap: ₹2.6K CrSector: Chemicals & Petrochemicals
Management growth scorecard
Revenue
N/A
Margin
N/A
Fundraise
N/A
Order
N/A
Capex
N/A
0 of 0 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
- Stallion India Fluorochemicals projects a robust CAGR of 30%-35% over the next three years.
- Growth driven by new facilities: semiconductor gas, specialty gases, and HFO-based refrigerants.
- Semiconductor gas facility to start sales in the last quarter of FY25, with significant revenue impact from FY26 onwards.
- New product introductions such as helium, argon, NFC, and other semiconductor gases expected to add around INR 100 crores each in revenues.
- Mambattu HFO facility also anticipated to contribute approx. INR 100 crores in revenue.
- Focus on backward integration to manufacture critical molecules supporting revenue growth.
- Expansion in Southern India with new plants to enhance market reach.
- Strategic growth expected from high-margin segments (semiconductor gases, HFOs, specialty gases) leading to increased sustainable margins.
- Plans for export expansion in Middle East, Africa, and Sri Lanka after domestic stabilization and CapEx completion.
See what Stallion India management said on margin guidance — free account, 30 seconds.
Fundraise plans
- There is no explicit mention of any current plans for new fundraising through debt or equity in the provided transcript.
- The company recently completed an IPO (around early 2023/2024) and has raised funds through it.
- Focus currently is on utilizing the IPO proceeds for CapEx related to new manufacturing facilities (specialty gas unit, HFO unit, Southern facility).
- The company plans to complete all their current CapEx and stabilization before considering further expansion or moves.
- No stated plan to raise additional funds before completing and stabilizing these projects, likely indicating no imminent fundraising via debt or equity.
See what Stallion India management said on order book — free account, 30 seconds.
Capex plans
- Ongoing CapEx is focused on two new manufacturing facilities: a semiconductor & specialty gas plant and an HFO (hydrofluoroolefin) plant in Mambattu, poised for completion by October 30, 2025.
- Plans to scale up the Mambattu facility from 5 to 10 tanks, enhancing capacity by 100%.
- CapEx spend as of March 31 was minimal (~INR 69 lakhs), with major procurement and construction starting in May 2025.
- Strategic emphasis on backward integration to manufacture key molecules in-house.
- New facilities enable entry into high-growth, high-margin sectors like semiconductor gases, HFO-based refrigerants, and specialty gases.
- Expansion into South India (new facility in Mambattu) to tap into underserved markets like Chennai, Bangalore, and Kochi.
- Future exports planned via Middle East and Sri Lanka as stepping stones to African and other regional markets, post-stabilization and CapEx completion.
- Total CapEx spend estimated around INR 51 crores for the upcoming facilities.
- Objective: Achieve sustainable 30-35% CAGR with margin accretion of 3-4% through these investments.
Track Stallion India — get its next earnings analysis in your feed
Margin guidance
- Stallion India Fluorochemicals targets a robust CAGR of 30-35% in revenue over the next three years.
- This growth is driven by new facilities including semiconductor gases and HFO production, adding approx. INR 200 crores in revenue.
- Expansion into high-margin segments like specialty gases, semiconductor-related gases, and HFOs expected to enhance EBITDA and PAT margins.
- The company anticipates margin improvement of about 3-4% through margin-accretive offerings.
- FY25 results showed strong operating performance: Q4 revenues at INR 153.16 crores (+79.87% QoQ), EBITDA INR 20.31 crores (+41.75% QoQ), PAT INR 13.27 crores (+35.56% QoQ).
- Backward integration and focus on higher-margin products aim to stabilize and sustainably improve earnings.
- A gradual shift in industry to HFOs and semiconductor gases is expected to provide stable, high-margin revenue streams with long gestation but entry barriers once approved.
- Overall, earnings and EPS growth are expected to be sustainable and credible based on current guidance and past performance.
Order book
The transcript on page 16 does not explicitly mention the current or expected order book or pending orders for Stallion India Fluorochemicals Limited. However, some relevant insights include:
- The company plans to expand its footprint in exports, targeting the Middle East and Africa via Dubai and Sri Lanka, focusing on shipping-related products.
- There is a focus on stabilizing domestic operations and completing capital expenditure before aggressive expansion.
- Growth drivers include new product launches such as semiconductor gases, specialty gases, and HFO refrigerants expected to add significant revenue.
- The company emphasizes managing raw material stock effectively to offset short-term supply fluctuations.
- Current capacity utilization is over 50%, with expansions underway to meet growing demand.
No explicit order book or pending order values are provided in the transcript.
How does Stallion India rank vs peers in Chemicals & Petrochemicals?
Pro featureThisStallion India
How does Stallion India rank in Chemicals & Petrochemicals?
Compare Stallion India against every Chemicals & Petrochemicals company (Q4 FY25) on revenue, margins and earnings-call signals.
Continue your research
What Stallion India's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Sudarshan Chemical Industries Ltd (Q1 FY27)
The net debt has already been reduced significantly from Rs.922 Crores at acquisition to Rs.531 Crores. Key concall takeaways from Sudarshan Chemical…
- Indo Borax & Ch. (Q1 FY27)
250-260 crores in FY27 with about 20% EBITDA margin, growing at 11-12% annually in absolute terms. Key concall takeaways from Indo Borax & Chemicals Ltd's Q1…
- SRF (Q1 FY27)
Chemicals business is guided for 15-20% growth in FY27, with a strong Q1 performance positioning the company to possibly hit the higher end of this range (Page…
- Deepak Fertilis. (Q1 FY27)
Long-term demand-supply balance looks stable with 6-7% market growth, supporting sustained revenues despite new capacity additions. Key concall takeaways from…